PT1140997E - Antigénios de chlamydia trachomatis - Google Patents

Antigénios de chlamydia trachomatis Download PDF

Info

Publication number
PT1140997E
PT1140997E PT99958455T PT99958455T PT1140997E PT 1140997 E PT1140997 E PT 1140997E PT 99958455 T PT99958455 T PT 99958455T PT 99958455 T PT99958455 T PT 99958455T PT 1140997 E PT1140997 E PT 1140997E
Authority
PT
Portugal
Prior art keywords
protein
proteins
chlamydia
quot
nucleic acid
Prior art date
Application number
PT99958455T
Other languages
English (en)
Portuguese (pt)
Inventor
Martin Arnold
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Publication of PT1140997E publication Critical patent/PT1140997E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/295—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Chlamydiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/125—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Chlamydiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56927—Chlamydia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT99958455T 1998-12-18 1999-12-17 Antigénios de chlamydia trachomatis PT1140997E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9828000.1A GB9828000D0 (en) 1998-12-18 1998-12-18 Antigens

Publications (1)

Publication Number Publication Date
PT1140997E true PT1140997E (pt) 2007-12-10

Family

ID=10844562

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99958455T PT1140997E (pt) 1998-12-18 1999-12-17 Antigénios de chlamydia trachomatis

Country Status (12)

Country Link
US (3) US20060188516A1 (enExample)
EP (3) EP1857464B1 (enExample)
JP (2) JP2002534062A (enExample)
AT (2) ATE516299T1 (enExample)
CA (1) CA2355876A1 (enExample)
CY (1) CY1107024T1 (enExample)
DE (1) DE69937004T2 (enExample)
DK (1) DK1140997T3 (enExample)
ES (1) ES2292261T3 (enExample)
GB (1) GB9828000D0 (enExample)
PT (1) PT1140997E (enExample)
WO (1) WO2000037494A2 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737413T2 (de) 1996-01-04 2007-10-31 Novartis Vaccines and Diagnostics, Inc., Emeryville Bakterioferritin aus helicobacter pylori
US6686339B1 (en) 1998-08-20 2004-02-03 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein C of Chlamydia
CA2340330A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding inclusion membrane protein c of chlamydia
CA2340283A1 (en) 1998-08-20 2000-03-02 Aventis Pasteur Limited Nucleic acid molecules encoding pomp91a protein of chlamydia
US6649370B1 (en) 1998-10-28 2003-11-18 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6607730B1 (en) 1998-11-02 2003-08-19 Aventis Pasteur Limited/Aventis Pasteur Limitee Chlamydia antigens and corresponding DNA fragments and uses thereof
WO2000032784A1 (en) 1998-12-01 2000-06-08 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
IL143531A0 (en) 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
GB9828000D0 (en) * 1998-12-18 1999-02-10 Chiron Spa Antigens
US7297341B1 (en) 1998-12-23 2007-11-20 Sanofi Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
US6808713B1 (en) 1998-12-28 2004-10-26 Aventis Pasteur Limited Chlamydia antigens and corresponding DNA fragments and uses thereof
CA2356057A1 (en) 1998-12-28 2000-07-06 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
MXPA01009256A (es) 1999-03-12 2003-07-14 Aventis Pasteur Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CA2395499C (en) 1999-12-22 2011-10-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
ATE348892T1 (de) 2000-05-08 2007-01-15 Sanofi Pasteur Ltd Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
ES2330083T3 (es) 2000-10-27 2009-12-04 Novartis Vaccines And Diagnostics S.R.L. Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ATE352316T1 (de) 2002-11-01 2007-02-15 Glaxosmithkline Biolog Sa Immunogene zusammensetzung
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
ATE437633T2 (de) 2003-06-02 2009-08-15 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
NZ561042A (en) 2005-02-18 2011-03-31 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
JP2009511636A (ja) 2005-10-18 2009-03-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
AU2006341122B2 (en) * 2005-12-22 2013-08-22 Novartis Vaccines And Diagnostics, Srl. Chlamydial antigens
WO2008019162A2 (en) 2006-01-18 2008-02-14 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
JP2010500399A (ja) 2006-08-16 2010-01-07 ノバルティス アーゲー 尿路病原性大腸菌由来の免疫原
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
JP5653215B2 (ja) 2007-09-12 2015-01-14 ノバルティス アーゲー Ｇａｓ５７変異体抗原およびｇａｓ５７抗体
CA2744739A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
EP2537857B1 (en) 2007-12-21 2017-01-18 GlaxoSmithKline Biologicals SA Mutant forms of streptolysin O
JP2012502972A (ja) 2008-09-18 2012-02-02 ノバルティス アーゲー ワクチンアジュバントの組み合わせ
DK2349520T3 (en) 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
CN102307477B (zh) 2009-01-05 2015-07-29 埃皮托吉尼西斯股份有限公司 佐剂组合物及使用方法
NZ594029A (en) 2009-01-12 2014-01-31 Novartis Ag Cna_b domain antigens in vaccines against gram positive bacteria
AU2010220103A1 (en) 2009-03-06 2011-09-22 Novartis Ag Chlamydia antigens
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
TR201802380T4 (tr) 2009-06-10 2018-03-21 Glaxosmithkline Biologicals Sa Benzonaftiridin içeren aşılar.
EP2443250B8 (en) 2009-06-16 2016-09-21 GlaxoSmithKline Biologicals SA High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
NZ598654A (en) 2009-09-02 2014-05-30 Novartis Ag Immunogenic compositions including tlr activity modulators
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CN102905703B (zh) 2010-03-23 2016-09-28 诺华股份有限公司 作为tlr2激动剂用于治疗感染、炎症、呼吸疾病等的化合物(基于半胱氨酸的脂肽)和组合物
AU2011237393B2 (en) 2010-04-08 2015-01-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education B-cell antigen presenting cell assay
KR20130121699A (ko) 2010-05-28 2013-11-06 테트리스 온라인, 인코포레이티드 상호작용 혼성 비동기 컴퓨터 게임 기반구조
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012082914A1 (en) 2010-12-14 2012-06-21 Novartis Ag Flow cytometry analysis of materials adsorbed to metal salts
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
CN103717235A (zh) 2011-06-24 2014-04-09 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
US9358284B2 (en) 2011-09-14 2016-06-07 Glaxosmithkline Biologicals Sa Methods for making saccharide-protein glycoconjugates
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
US9320748B2 (en) 2012-03-07 2016-04-26 Novartis Ag Immunologically useful arginine salts
RU2014140521A (ru) 2012-03-08 2016-04-27 Новартис Аг Адъювантные составы бустерных вакцин
MX2014014067A (es) 2012-05-22 2015-02-04 Novartis Ag Conjugado de serogrupo x de meningococo.
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
JP7005504B2 (ja) 2016-02-22 2022-01-21 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 生体分子の固定化方法
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
NL2019320B1 (en) * 2017-03-02 2018-09-21 Biosparq B V Diagnostic method and system for diagnosis
CA3090271A1 (en) 2018-02-12 2019-08-15 Inimmune Corporation Toll-like receptor ligands
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
IL302449A (en) 2020-11-04 2023-06-01 Eligo Bioscience CUTIBACTERIUM ACNES PHAGES RECOMBINANT, the production method and their uses
CN113637703B (zh) * 2021-08-06 2023-08-25 河北科技师范学院 一种布鲁氏菌L7/L12和GroES真核表达载体的构建方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1244706B (it) 1991-02-07 1994-08-08 Sclavo Spa Plasmide pctd isolato da chlamydia trachomatis serotipo d, suoi geni e proteine da essi codificate; plasmidi ricombinanti per l'espressionedi detti geni in sistemi eterologhi come proteine ricombinanti di fusione, preparazione di dette proteine ricombinanti e loro uso nella formulazione di vaccini e/o diagnostici
US5629167A (en) * 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
KR100769104B1 (ko) 1997-11-28 2007-10-23 세로노 제네틱스 인스티튜트 에스.에이. 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
CA2326002A1 (en) 1998-04-20 1999-10-28 The State Of Oregon Acting By And Through The State Board Of Higher Educ Ation On Behalf Of Oregon State University Chlamydia proteins and their uses
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
CA2350775A1 (en) 1998-11-12 2000-05-18 The Regents Of The University Of California Chlamydia pneumoniae genome sequence
US6565856B1 (en) 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020061848A1 (en) 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
IL143531A0 (en) 1998-12-08 2002-04-21 Corixa Corp Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
GB9902555D0 (en) 1999-02-05 1999-03-24 Neutec Pharma Plc Medicament
US20030095973A1 (en) 1999-05-03 2003-05-22 Murdin Andrew D. Chlamydia antigens and corresponding DNA fragments and uses thereof
NZ517952A (en) 1999-09-20 2004-01-30 Aventis Pasteur Chlamydia antigens and corresponding DNA fragments and uses thereof
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
CA2395499C (en) 1999-12-22 2011-10-25 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
DE60133190T2 (de) 2000-04-21 2009-04-02 CORIXA CORP., Wilmington Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
ATE348892T1 (de) 2000-05-08 2007-01-15 Sanofi Pasteur Ltd Chlamydia antigene, entsprechende dns fragmente und ihre verwendungen
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
EP1412757A2 (en) 2001-04-09 2004-04-28 Allan Christian Shaw Method for identification of proteins from intracellular bacteria

Also Published As

Publication number Publication date
EP1140997A2 (en) 2001-10-10
US20100098697A1 (en) 2010-04-22
EP1857464B1 (en) 2011-07-13
US20060188516A1 (en) 2006-08-24
ATE371668T1 (de) 2007-09-15
JP2002534062A (ja) 2002-10-15
EP1140997B1 (en) 2007-08-29
GB9828000D0 (en) 1999-02-10
WO2000037494A2 (en) 2000-06-29
EP1598362A3 (en) 2006-03-22
EP1857464A3 (en) 2008-04-02
US8114401B2 (en) 2012-02-14
ES2292261T3 (es) 2008-03-01
ATE516299T1 (de) 2011-07-15
DK1140997T3 (da) 2007-12-27
WO2000037494A3 (en) 2000-10-12
CA2355876A1 (en) 2000-06-29
DE69937004T2 (de) 2008-05-21
JP2010220622A (ja) 2010-10-07
US20130156775A1 (en) 2013-06-20
EP1598362A2 (en) 2005-11-23
DE69937004D1 (de) 2007-10-11
EP1857464A2 (en) 2007-11-21
CY1107024T1 (el) 2012-09-26

Similar Documents

Publication Publication Date Title
PT1140997E (pt) Antigénios de chlamydia trachomatis
Stephens et al. High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of Chlamydia trachomatis.
US5567594A (en) Methods and compositions for the detection and treatment of diseases associated with antigens of microorganisms
Coleman et al. Identification and characterization of an endoflagellar antigen of Borrelia burgdorferi.
JP3920320B2 (ja) 精製されたＨｅｌｉｃｏｂａｃｔｅｒ ｐｙｌｏｒｉ由来の空胞形成毒素およびその使用方法
Batteiger The major outer membrane protein of a single Chlamydia trachomatis serovar can possess more than one serovar-specific epitope
Tomson et al. Assessment of cell-surface exposure and vaccinogenic potentials of Treponema pallidum candidate outer membrane proteins
Fan et al. Antigen conformation dependence of Chlamydia trachomatis infectivity neutralization
Kawa et al. Antigenic topology of chlamydial PorB protein and identification of targets for immune neutralization of infectivity
CA2190359C (en) Nucleic acids of rochalimaea henselae and rochalimaea quintana and methods and compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection
Feng et al. A 55-kilodalton antigen encoded by a gene on a Borrelia burgdorferi 49-kilobase plasmid is recognized by antibodies in sera from patients with Lyme disease
Frikha-Gargouri et al. Evaluation of an in silico predicted specific and immunogenic antigen from the OmcB protein for the serodiagnosis of Chlamydia trachomatis infections
Rauer et al. Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease
Hansen Laboratory diagnostic methods in Lyme borreliosis
EP0827591A1 (en) Method for diagnosing a patient for chlamydia
Larsen et al. The humoral immune response to Chlamydia trachomatis in patients with acute reactive arthritis
AU2009227986A1 (en) Novel sequences of Brachyspira, immunogenic compositions, methods for preparation and use thereof
US20020012919A1 (en) Nucleic acids of rochalimaea henselae and methods and compositions for diagnosing rochalimaea henselae and rochalimaea quintana infection
AU2010212926B2 (en) Device for serologically detecting Yersinia infections and/or secondary diseases thereof and use of the proteins MyfA and PsaA of Y. enterocolitica and Y. pseudotuberculosis as recombinant antigens
JP2001286295A (ja) クラミジア・トラコマチス検出用抗体
Feodorova et al. Preparative Obtaining of Murine Diagnostic Anti-Chlamydia Antibodies using Direct Immunogenesis
Vogt et al. Enzyme-Linked Immunosorbent Assay Using
JPWO1996007910A1 (ja) クラミジア感染症の診断薬